Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-dense ABVD in Early Stage Unfavorable Hodgkin's Lymphoma
NCT02247869Phase 2Completed
- Sponsor
- Fondazione Italiana Linfomi
- Start
- Feb 2012
- Primary completion
- Jun 2015
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
A Phase 2 trial of pegylated liposomal doxorubicin, bleomycin, vinblastine, dacarbazine in Hodgkin lymphoma (HL), sponsored by Fondazione Italiana Linfomi. Started Feb 2012; status: completed.
02
Drugs
pegylated liposomal doxorubicinbleomycinvinblastinedacarbazine
03
Conditions
Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT02247869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02247869.